{"prompt": "['CONFIDENTIAL', 'Verrica Pharmaceuticals, Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', 'CONFIDENTIAL', 'CLINICAL PROTOCOL', 'TITLE OF STUDY:', 'A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of VP-', '102 Topical Film Forming Solution [0.7% (w/v) cantharidin] in Subjects (2 years and older)', 'with Molluscum Contagiosum', 'Protocol VP-102-103', 'Date of issue: 08 August 2017', 'Version number: 2.1', 'Sponsor:', 'Verrica Pharmaceuticals, Inc.', '200 Garrett St#S', 'Charlottesville, VA 22902']['CONFIDENTIAL', 'Verrica Pharmaceuticals, Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', 'Signatures of Approval of Protocol (Version 2.1)', 'This protocol was subject to critical review and has been approved by the following persons:', 'Affiliation', 'Name', 'Signature', 'Date:', 'Sponsor:', 'Cincly Willson R.U Currio', '11/17/17', 'Medical', 'Laurie Dunn, MD', 'Laure and', '8/29/17', 'Monitor:', 'Sponsor:', 'Verrica Pharmaceuticals, Inc.', '200 Garrett St#S', 'Charlottesville, VA 22902', 'Sponsor contact:', 'Cindy Willson, RN. BSN', 'Clinical Operations Director', '200 Garrett St#S', 'Charlottesville. VA 22902', 'Phone: 628-400-7617', 'Email cindy@verricapharmaceuticals.com', 'Medical monitor:', 'Laurie Dunn, MD', 'Paidion Research, Inc.', '240 Leigh Farm Road. Suite 250', 'Durham. NC 27707', 'Phone: 919-810-5767', 'E-mail: Laurie.Dunn@@Paidion.com', 'Page 2']['CONFIDENTIAL', 'Verrica Pharmaceuticals Inc.', 'VP-102', 'Clinical Protocol: VP-102-103', 'Acknowledgment of Responsibilities (Protocol Version 2.1)', 'This protocol is the property of Verrica Pharmaceuticals, Inc. I understand that the information within it is confidential', 'and is provided to me for review by myself, my staff, and applicable ethics committees. I understand that the protocol', 'must be kept in a confidential manner and must be returned to the Sponsor Verrica Pharmaceuticals, Inc., or destroyed', 'per Verrica Pharmaceuticals, Inc. instructions, upon request. No part of this protocol may be reproduced in any form', 'without written authorization from Verrica Pharmaceuticals, Inc. By accepting this protocol, I agree that the', 'information contained herein will not be disclosed to a third party without written authorization from Verrica', 'Pharmaceuticals, Inc.', 'I have read and understood the protocol and agree that it contains all of the necessary information to carry out the', 'study.', 'I agree to conduct this trial in accordance with all stipulations of the protocol and in accordance with the following:', 'Good Clinical Practice, the ethical principles that have their origin in the Declaration of Helsinki; Title 21 of the Code', 'of Federal Regulations, Parts 50 (Protection of Human Subjects), and 56 (Institutional Review Boards), and 312', '(Investigational New Drug Application); and International Council for Harmonisation E6 (Guideline for Good Clinical', 'Practice).', 'I agree that I will not modify this protocol without obtaining the prior approval of the sponsor and of the institutional', 'review board or independent ethics committee, except when necessary to protect the safety, rights, or welfare of', 'subjects.', 'Institution Name', 'Investigator Name', 'Signature', 'Date', 'Page 3']\n\n###\n\n", "completion": "END"}